Plus   Neg

Stock Alert: La Jolla Pharmaceutical Soars On Deal With PAION

Shares of La Jolla Pharmaceutical Company (LJPC) are surging more than 40% Tuesday morning after it entered into an exclusive licensing agreement with PAION AG and its wholly owned subsidiary for GIAPREZA (angiotensin II) and XERAVA (eravacycline) in the European Economic Area, the United Kingdom and Switzerland.

As per the deal, La Jolla is entitled to receive an upfront cash payment of $22.5 million, commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA.

La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the Territories.

GIAPREZA and XERAVA are approved by the FDA as well as the European Commission.

LJPC, currently at $5.71, has been trading in the range of $3.36- $9.38 in the last one year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Netflix Inc. (NFLX) - Shares of the video streaming giant jumped 12% after it reported fourth-quarter results and strong subscriber additions. Netflix added 8.51 million subscribers globally in the quarter, far ahead of its forecast of 6.00 million, to end the quarter with 203.66 million subscribers.... Best Buy said it is partnering Popsockets to bring products designed by teens from the company's community programs to its store shelves. The electronics retailer will sell the teen-designed PopGrips in its stores as part of its "Black History Month" campaign. The campaign is intended to celebrate and encourage young artists. Goldman Sachs Group Inc. (GS) on Tuesday reported a fourth-quarter profit that more than doubled from last year, reflecting a surge in investment banking revenues and lower provisions for bad loans. Net revenues for the quarter rose 18 percent. Both quarterly earnings per share and revenues topped analysts' expectations.
Follow RTT